Role of Long Non-Coding RNAs in the Chemoresistance of Gastric Cancer: A Systematic Review

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Engreitz JM, Ollikainen N, Guttman M. Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nat Rev Mol Cell Biol. 2016;17:756–770.
   PubMed Web of Science ®Google Scholar
• Kretz M, Siprashvili Z, Chu C, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature. 2013;493:231–235.
   PubMed Web of Science ®Google Scholar
• Uthaya Kumar DB, Williams A. Long non-coding RNAs in immune regulation and their potential as therapeutic targets. Int Immunopharmacol. 2020;81:106279.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu H, Chen S. Mechanisms of long non-coding RNAs in cancers and their dynamic regulations. Cancers. 2020;12:1245.
   PubMed Web of Science ®Google Scholar
• Jiang W, Kai J, Li D, Wei Z, Wang Y, Wang W. lncRNA HOXB-AS3 exacerbates proliferation, migration, and invasion of lung cancer via activating the PI3K-AKT pathway. J Cell Physiol. 2020.
   Web of Science ®Google Scholar
• Li Y, Guo X, Wei Y. LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. Eur Rev Med Pharmacol Sci. 2020;24:4873.
   PubMed Web of Science ®Google Scholar
• Lan Y, Xiao X, He Z, et al. Long noncoding RNA OCC-1 suppresses cell growth through destabilizing HuR protein in colorectal cancer. Nucleic Acids Res. 2018;46:5809–5821.
   PubMed Web of Science ®Google Scholar
• Liu K, Gao L, Ma X, et al. Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer. 2020;19:13–54.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Ren N, Jiang T, Wang C, et al. LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis. Aging. 2020;12:11025–11041.
   PubMedGoogle Scholar
• Lan WG, Xu DH, Xu C, et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep. 2016;36:263–270.
   PubMed Web of Science ®Google Scholar
• Zhu L, Zhu Y, Han S, et al. Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer. Cell Death Dis. 2019;10.
   Web of Science ®Google Scholar
• Hang Q, Sun R, Jiang C, Li Y. Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. Anti-Cancer Drug. 2015;1.
   PubMed Web of Science ®Google Scholar
• Fu T, Ji K, Jin L, et al. ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer. Gastric Cancer. 2020.
   Web of Science ®Google Scholar
• Wang L, Chunyan Q, Zhou Y, et al. BCAR4 increase cisplatin resistance and predicted poor survival in gastric cancer patients. Eur Rev Med Pharmacol Sci. 2017;21:4064–4070.
   PubMed Web of Science ®Google Scholar
• Li Y, Lv S, Ning H, et al. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomed Pharmacother. 2018;108:1775–1782.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Q, Xu G, et al. The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells. RNA Biol. 2020;1–14.
   Web of Science ®Google Scholar
• Xu YD, Shang J, Li M, Zhang YY. LncRNA DANCR accelerates the development of multidrug resistance of gastric cancer. Eur Rev Med Pharmacol Sci. 2019;23:2794–2802.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Q, Yu S, et al. Long non-coding RNA FAM84B-AS promotes resistance of gastric cancer to platinum drugs through inhibition of FAM84B expression. Biochem Bioph Res Co. 2019;509:753–762.
   PubMed Web of Science ®Google Scholar
• Zhang X, Bo P, Liu L, Zhang X, Li J. Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed Pharmacother. 2017;92:580–585.
   PubMed Web of Science ®Google Scholar
• Cheng C, Qin Y, Zhi Q, Wang J, Qin C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/beta-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018;107:2620–2629.
   PubMed Web of Science ®Google Scholar
• Yan J, Dang Y, Liu S, Zhang Y, Zhang G. LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumor Biology. 2016;37:16345–16355.
   Google Scholar
• Wang J, Lv B, Su Y, Wang X, Bu J, Yao L. Exosome-mediated transfer of lncRNA HOTTIP promotes cisplatin resistance in gastric cancer cells by regulating HMGA1/miR-218 axis. Onco Targets Ther. 2019;12:11325–11338.
   PubMed Web of Science ®Google Scholar
• Mao Z, Wu Y, Zhou J, Xing C. Salinomycin reduces epithelial-mesenchymal transition-mediated multidrug resistance by modifying long noncoding RNA HOTTIP expression in gastric cancer cells. Anticancer Drugs. 2019;30:892–899.
   PubMed Web of Science ®Google Scholar
• Xin L, Zhou Q, Yuan YW, et al. METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy. J Cancer Res Clin Oncol. 2019;145:2507–2517.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Song X, Wang X, Hu J, Jiang L. Silencing of LncRNA HULC enhances chemotherapy induced apoptosis in human gastric cancer. J Med Biochem. 2016;35:137–143.
   PubMed Web of Science ®Google Scholar
• YiRen H, YingCong Y, Sunwu Y, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017;16.
   PubMed Web of Science ®Google Scholar
• Dai Q, Zhang T, Li C. LncRNA MALAT1 regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K/AKT pathway. Cancer Manag Res. 2020;12:1929–1939.
   PubMed Web of Science ®Google Scholar
• Xi Z, Si J, Nan J. LncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the microRNA30b/autophagy-related gene 5 axis in gastric cancer. Int J Oncol. 2019;54:239–248.
   PubMed Web of Science ®Google Scholar
• Zhang YF, Li CS, Zhou Y, Lu XH. Propofol facilitates cisplatin sensitivity via lncRNA MALAT1/miR-30e/ATG5 axis through suppressing autophagy in gastric cancer. Life Sci. 2020;244:117280.
   PubMed Web of Science ®Google Scholar
• Li H, Ma X, Yang D, Suo Z, Dai R, Liu C. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2. J Cell Biochem. 2019;121:1353–1361.
   PubMed Web of Science ®Google Scholar
• Guo Y, Yue P, Wang Y, Chen G, Li Y. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis. Biomed Pharmacother. 2019;118:109255.
   PubMed Web of Science ®Google Scholar
• Zhang X, Bu P, Liu L, Zhang X, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Bioph Res Co. 2015;462:227–232.
   PubMed Web of Science ®Google Scholar
• Wu C, Hu Y, Ning Y, Zhao A, Zhang G, Yan L. Long noncoding RNA plasmacytoma variant translocation 1 regulates cisplatin resistance via miR-3619-5p/TBL1XR1 axis in gastric cancer. Cancer Biother Radio. 2020.
   Web of Science ®Google Scholar
• Jin W, Zhang H, Li M, Lin S. Long noncoding RNA regulator of reprogramming regulates cell growth, metastasis, and cisplatin resistance in gastric cancer via miR-519d-3p/HMGA2 Axis. Cancer Biother Radio. 2020.
   Web of Science ®Google Scholar
• Li M, Zhang YY, Shang J, Xu YD. LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis. Eur Rev Med Pharmacol Sci. 2019;23:4185–4191.
   PubMed Web of Science ®Google Scholar
• Dai Q, Zhang T, Pan J, Li C. LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway. J Cancer. 2020;11:3882–3892.
   PubMed Web of Science ®Google Scholar
• Fang Q, Chen X, Zhi X. Long non-coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) increases multi-drug resistance of gastric cancer via downregulating miR-27b. Med Sci Monitor. 2016;22:3506–3513.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Q, Tang X. Long non-coding RNA XIST contributes into drug resistance of gastric cancer cell. Minerva Med. 2019;110:270–272.
   PubMed Web of Science ®Google Scholar
• Zeng L, Liao Q, Zou Z, et al. Long non-coding RNA XLOC_006753 promotes the development of multidrug resistance in gastric cancer cells through the PI3K/AKT/mTOR signaling pathway. Cell Physiol Biochem. 2018;51:1221–1236.
   PubMedGoogle Scholar
• Xu W, He L, Li Y, Tan Y, Zhang F, Xu H. Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/beta-catenin signaling in gastric cancer cells. Biosci Biotechnol Biochem. 2018;82:456–465.
   PubMed Web of Science ®Google Scholar
• Wu X, Zheng Y, Han B, Dong X. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother. 2018;99:832–838.
   PubMed Web of Science ®Google Scholar
• Song W, Qian Y, Zhang MH, et al. The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24:3049–3061.
   PubMed Web of Science ®Google Scholar
• Wu H, Liu B, Chen Z, Li G, Zhang Z. MSC-induced lncRNA HCP5 drove fatty acid oxidation through miR-3619-5p/AMPK/PGC1α/CEBPB axis to promote stemness and chemo-resistance of gastric cancer. Cell Death Dis. 2020;11.
   PubMed Web of Science ®Google Scholar
• He W, Liang B, Wang C, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019;38:4637–4654.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li M, Zhang Z. lncRNA MALAT1 modulates oxaliplatin resistance of gastric cancer via sponging miR-22-3p. Onco Targets Ther. 2020;13:1343–1354.
   PubMed Web of Science ®Google Scholar
• Han Y, Ye J, Wu D, et al. LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. Bmc Cancer. 2014;14:932.
   PubMed Web of Science ®Google Scholar
• Du P, Hu C, Qin Y, et al. LncRNA PVT1 mediates antiapoptosis and 5-fluorouracil resistance via increasing Bcl2 expression in gastric cancer. J Oncol. 2019;2019:9325407.
   PubMed Web of Science ®Google Scholar
• Shang C, Sun L, Zhang J, et al. Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance. Oncotarget. 2017;8:15393–15398.
   PubMedGoogle Scholar
• Zhou Z, Lin Z, He Y, et al. The long noncoding RNA D63785 regulates chemotherapy sensitivity in human gastric cancer by targeting miR-422a. Molecular Therapy - Nucleic Acids. 2018;12:405–419.
   Google Scholar
• Ding H, Sun J, Li R, Wang G. Long non-coding RNA GACAT1 alleviates doxorubicin and vincristine resistance through a PTEN/AKT/mTOR/S6K1 regulatory pathway in gastric cancer. RSC Adv. 2019;9:8048–8055.
   PubMed Web of Science ®Google Scholar
• Wang H, Qin R, Guan A, et al. HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression. J Cell Biochem. 2018;119:7226–7234.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014;34:3182–3193.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhao B, Chen X, Wang Z, Xu H, Huang B. Silence of long noncoding RNA NEAT1 inhibits malignant biological behaviors and chemotherapy resistance in gastric cancer. Pathology Oncol Res. 2017;24:109–113.
   PubMed Web of Science ®Google Scholar
• Wang S, Chen W, Yu H, et al. lncRNA ROR promotes gastric cancer drug resistance. Cancer Control. 2020;27:544330725.
   Web of Science ®Google Scholar
• Shang C, Guo Y, Zhang J, Huang B. Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer. Cancer Chemother Pharm. 2016;77:1061–1067.
   PubMed Web of Science ®Google Scholar
• Ding J, Li D, Gong M, et al. Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. Onco Targets Ther. 2014;7:1625–1630.
   PubMed Web of Science ®Google Scholar
• Arnold M, Park JY, Camargo MC, Lunet N, Forman D, Soerjomataram I. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020;69:823–829.
   PubMed Web of Science ®Google Scholar
• Li ZL, Jiang HW, Song M, Xu L, Xia D, Liu Q. Secondary sentinel lymph node tracing technique: a new method for tracing lymph nodes in radical gastrectomy for advanced gastric cancer. J Zhejiang Univ Sci B. 2015;16:897–903.
   PubMed Web of Science ®Google Scholar
• Poursheikhani A, Bahmanpour Z, Razmara E, et al. Non-coding RNAs underlying chemoresistance in gastric cancer. Cell Oncol. 2020.
   Web of Science ®Google Scholar
• Ruan T, Liu W, Tao K, Wu C. A review of research progress in multidrug-resistance mechanisms in gastric cancer. Onco Targets Ther. 2020;13:1797–1807.
   PubMed Web of Science ®Google Scholar
• Mirzaei H, Hamblin MR. Regulation of glycolysis by non-coding RNAs in cancer: switching on the warburg effect. Mol Ther Oncolytics. 2020;19:218–239.
   PubMed Web of Science ®Google Scholar
• Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 2017;18:206.
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–3981.
   PubMed Web of Science ®Google Scholar
• Wang Z, Qin B. Prognostic and clinicopathological significance of long noncoding RNA CTD-2510F5.4 in gastric cancer. Gastric Cancer. 2019;22:692–704.
   PubMed Web of Science ®Google Scholar
• Chong DQ, Shan JL, Yang CS, Wang R, Du ZM. Clinical prognostic value of A FOXM1 related long non-coding RNA expression in gastric cancer. Eur Rev Med Pharmacol Sci. 2018;22:417–421.
   PubMed Web of Science ®Google Scholar
• Wei L, Sun J, Zhang N, et al. Noncoding RNAs in gastric cancer: implications for drug resistance. Mol Cancer. 2020;19:62.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xie K, Zhou H, et al. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 2020;19:47.
   PubMed Web of Science ®Google Scholar